Tag: litigation

COLUMBUS, Ohio, June 05, 2025 (GLOBE NEWSWIRE) -- Bread Financial Holdings, Inc. (NYSE: BFH) (“Bread Financial” or the “Company”) announced that as of 5:00 p.m., New York City time, on June 4, 2025 (the “Early Participation Date”), pursuant to and in accordance with its previously announced cash tender offer (the “Tender Offer”), approximately $536,786,000 in aggregate principal amount of the Company’s 9.750% Senior Notes due 2029 (the “Notes”) had been validly tendered and not validly withdrawn on or prior to the Early Participation Date, which, if and when accepted for purchase up to $150,000,000 in aggregate principal amount of Notes (the “Tender Cap”) by the Company pursuant to the terms and conditions of the Tender Offer, would result in Total Consideration (as defined below) (excluding accrued interest payable) of $1,071.25 for each $1,000 principal amount of Notes, which Total Consideration was determined in accordance with the terms of the Tender Offer based on the principal amount of Notes tendered and the Bid Premiums (as defined in the Offer to Purchase (as defined below)) at which such tenders were made.

Combination Delivers Unmatched Innovation in Arm-based Vulnerability and Malware Research, Smart Device DevSecOps and Mobile Pen Testing

New leadership focuses on business simplification and brand enablers

UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 05 juin 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS) (« Merus », la « Société », « nous » et « notre »), une société spécialisée dans l’oncologie qui développe des anticorps multispécifiques innovants et des conjugués anticorps-médicaments (Biclonics^®, Triclonics^® et ADClonics^®), a annoncé aujourd’hui le lancement d’une offre publique de souscription de ses actions ordinaires (les « Actions de l’offre »). Toutes les actions ordinaires sont proposées par Merus. En outre, Merus prévoit d’accorder aux souscripteurs une option de 30 jours leur permettant d’acheter jusqu’à 15 % supplémentaires des Actions de l’offre (les « Actions optionnelles » et collectivement avec les Actions de l’offre, les « Actions »). L’offre est soumise aux conditions du marché et à d’autres conditions de clôture. Aucune garantie ne saura être donnée quant au fait que l’offre sera réalisée ni le moment auquel cela interviendra ou encore sa taille réelle ou ses modalités.

Recent independent analyses confirmed that the Company has successfully created a ligand conjugated nanoparticle that can target specific biomarkers on the surface of cancer cells

HYDERABAD, INDIA & REYKJAVIK, ICELAND (June 5, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide (“Alvotech”), and Dr. Reddy’s Laboratories Ltd., (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as “Dr. Reddy’s”), today announced that the companies have entered into a collaboration and license agreement to co-develop, manufacture and commercialize a biosimilar candidate to Keytruda® (pembrolizumab) for global markets. Keytruda® (pembrolizumab) is indicated for the treatment of numerous cancer types. In 2024, worldwide sales of Keytruda were US$29.5 billion [1]. The collaboration combines Dr. Reddy’s and Alvotech’s proven capabilities in biosimilars, thereby, speeding up the development process and extending the global reach for this biosimilar candidate.

NASHVILLE, Tenn., June 04, 2025 (GLOBE NEWSWIRE) -- Ryman Hospitality Properties, Inc. (NYSE: RHP) (the “Company”) announced today that its subsidiaries, RHP Hotel Properties, LP (the “Operating Partnership”) and RHP Finance Corporation (together with the Operating Partnership, the “Issuers”), completed the previously announced private placement of $625 million aggregate principal amount of 6.500% senior notes due 2033 (the “Notes”). The Notes are senior unsecured obligations of the Issuers and are guaranteed by the Company and its subsidiaries that guarantee the Operating Partnership’s existing credit facility, 4.750% senior unsecured notes due 2027, 7.250% senior unsecured notes due 2028, 4.500% senior unsecured notes due 2029 and 6.500% senior unsecured notes due 2032. The aggregate net proceeds from the sale of the Notes are expected to be approximately $614 million, after deducting the initial purchasers’ discounts and commissions and estimated offering expenses.

BOCA RATON, FL, June 04, 2025 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (the “Company” or “DeFi Dev Corp.”), the first US public company with a treasury strategy built to accumulate and compound Solana (“SOL”), today announced a strategic partnership with Fragmetric, a pioneering native liquid restaking protocol built on Solana. As part of the collaboration, Fragmetric will be integrating the dfdvSOL Liquid Staking Token (LST) into its restaking platform, making dfdvSOL one of only five LSTs currently supported by the protocol.